Valuation Metrics and Recent Changes
As of 2 June 2026, Glenmark Pharma’s price-to-earnings (P/E) ratio stands at 22.03, reflecting a slight increase but still within an attractive range compared to historical averages and sector peers. The price-to-book value (P/BV) ratio is 5.92, indicating a premium valuation relative to book value but justified by the company’s robust return metrics. The enterprise value to EBITDA (EV/EBITDA) ratio is 13.48, which remains competitive within the pharmaceutical sector.
These valuation parameters have prompted a recalibration of the company’s mojo grade from a Strong Buy to a Buy, effective 1 June 2026, with a current mojo score of 71.0. This adjustment reflects a more balanced view of the stock’s price attractiveness, acknowledging the recent price correction while recognising the company’s strong fundamentals.
Comparative Peer Analysis
When benchmarked against key industry peers, Glenmark Pharma’s valuation remains appealing. For instance, Zydus Lifesciences trades at a P/E of 20.09 and EV/EBITDA of 13.54, also rated attractive. Lupin, another peer, has a P/E of 17.93 and EV/EBITDA of 11.42, similarly attractive but slightly lower on valuation multiples. In contrast, companies like Mankind Pharma and Laurus Labs are classified as expensive or very expensive, with P/E ratios of 47.24 and 84.22 respectively, and significantly higher EV/EBITDA multiples.
Biocon, despite a very attractive valuation grade, trades at a much higher P/E of 91.36, reflecting different growth expectations and market positioning. This comparative framework underscores Glenmark’s relative value proposition within the mid-cap pharmaceutical universe.
Financial Performance and Return Metrics
Glenmark’s operational efficiency is highlighted by its return on capital employed (ROCE) of 40.27% and return on equity (ROE) of 26.86%, both indicative of strong profitability and capital utilisation. The company’s PEG ratio of 0.18 further suggests undervaluation relative to earnings growth potential, a key metric for growth-oriented investors.
Dividend yield remains modest at 0.23%, consistent with the company’s reinvestment strategy to fuel growth and innovation in its product pipeline.
Stock Price Movement and Market Context
On 2 June 2026, Glenmark’s stock closed at ₹2,201.20, down 3.21% from the previous close of ₹2,274.25. The day’s trading range was between ₹2,180.00 and ₹2,299.95, with the 52-week high at ₹2,471.05 and low at ₹1,448.50. Despite the recent short-term weakness, the stock has delivered impressive returns over longer horizons, outperforming the Sensex significantly.
Year-to-date, Glenmark has returned 8.12%, compared to a Sensex decline of 12.85%. Over one year, the stock surged 51.00%, while the Sensex fell 8.82%. The three-year and five-year returns are particularly striking at 261.56% and 270.17% respectively, dwarfing the Sensex’s 18.96% and 43.00% gains over the same periods. Even over a decade, Glenmark’s 158.60% return remains competitive against the Sensex’s 178.01%.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Valuation Grade Evolution and Market Implications
The shift in Glenmark’s valuation grade from very attractive to attractive reflects a nuanced market reassessment. While the company’s fundamentals remain robust, the recent price appreciation has moderated the margin of safety for new investors. This recalibration is consistent with prudent risk management, signalling that while the stock remains a buy, investors should be mindful of valuation levels relative to growth prospects.
Moreover, the mid-cap classification of Glenmark Pharma implies a degree of volatility and growth potential that differs from large-cap pharmaceutical giants. Investors with a medium to long-term horizon may find the current valuation levels conducive to accumulation, especially given the company’s strong return ratios and growth trajectory.
Sector and Industry Context
The Pharmaceuticals & Biotechnology sector continues to attract investor interest due to its defensive characteristics and growth potential driven by innovation and increasing healthcare demand. Glenmark’s positioning within this sector, supported by a solid product pipeline and operational efficiency, enhances its appeal despite recent market fluctuations.
Comparatively, Glenmark’s valuation metrics are well aligned with sector averages, and its PEG ratio of 0.18 is particularly compelling against peers, signalling undervaluation relative to earnings growth. This metric is crucial for investors seeking growth stocks with reasonable valuations.
Thinking about Glenmark Pharmaceuticals Ltd.? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this mid-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Investment Outlook and Considerations
Investors evaluating Glenmark Pharmaceuticals should weigh the company’s strong financial health, attractive valuation relative to peers, and impressive long-term returns against the recent price volatility and sector dynamics. The downgrade in mojo grade from Strong Buy to Buy does not diminish the stock’s appeal but rather reflects a more calibrated assessment of risk and reward.
Given the company’s mid-cap status, investors should be prepared for potential short-term fluctuations while focusing on the long-term growth story supported by innovation, operational efficiency, and market expansion. The current valuation metrics, particularly the PEG ratio and return ratios, suggest that Glenmark remains a compelling candidate for portfolios seeking pharmaceutical sector exposure with growth orientation.
Summary
Glenmark Pharmaceuticals Ltd. continues to demonstrate strong fundamentals and attractive valuation metrics within the Pharmaceuticals & Biotechnology sector. The recent shift in valuation grade to attractive, alongside a mojo score of 71.0 and a Buy rating, signals a favourable investment opportunity for discerning investors. While the stock has experienced a short-term price correction, its long-term performance and relative valuation against peers underscore its potential as a mid-cap growth stock with solid financial health.
Investors should monitor ongoing sector developments and company-specific catalysts to capitalise on Glenmark’s growth trajectory while managing valuation risks prudently.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
